Abstract
Background
Atherosclerosis is widely accepted as a chronic inflammatory disease. Research paid much attention to sensitive specific serum biomarkers for vulnerable plaques. The markers not only serve as diagnostic tools for the identification of patients with acute coronary syndrome (ACS), but also help us to identify high‐risk patients. However, the existing data are limited and have been conflicting.
Hypothesis
Circulating interleukin‐6 (IL‐6), soluble CD40 ligand (sCD40L), metalloproteinase‐9 (MMP‐9), and tissue inhibitor of metalloproteinase‐1 (TIMP‐1) might correlate with the onset and the cardiac mortality of patients with ST‐segment elevation myocardial infarction (STEMI).
Methods
Serum levels of IL‐6, sCD40L, MMP‐9, and TIMP‐1 were measured by sandwich enzyme‐linked immunosorbent assay (ELISA) in 263 patients with STEMI and 262 age‐ and gender‐matched control subjects without coronary artery disease (CAD). The patients with STEMI were then followed prospectively for 24 mo for the occurrence of cardiac mortality.
Results
Compared with the control subjects, patients with STEMI exhibited higher levels of IL‐6 (p < 0.001), sCD40L (p < 0.001), MMP‐9 (p < 0.001), TIMP‐1 (p = 0.045), and MMP‐9/TIMP‐1 ratio (p = 0.007). Significant and positive correlations between MMP‐9 and TIMP‐1 (r = 0.610, p≤0.001]), IL‐6 and creatine kinase (CK) (r = 0.159, p = 0.022), and IL‐6 and Troponin‐I (TnI) (r = 0.141, p = 0.042) were observed by Spearman's correlations analysis. Logistic regression analysis revealed that IL‐6 significantly and independently correlated with the occurrence of STEMI, and IL‐6 was an independent predictor for cardiac mortality during a 24‐mo follow‐up in patients with STEMI.
Conclusion
The present study indicates that elevated admission level of IL‐6, but not of sCD40L, MMP‐9, or TIMP‐1, might indicate the onset of STEMI, and could provide prognostic value for future cardiac mortality within 2 y in patients with STEMI. Copyright © 2008 Wiley Periodicals, Inc.
Keywords: myocardial infarction, cytokine, inflammation
Full Text
The Full Text of this article is available as a PDF (190.3 KB).
References
- 1. Ross R: Atherosclerosis‐ an inflammatory disease. N Engl J Med 1999; 340: 115–126. [DOI] [PubMed] [Google Scholar]
- 2. Libby P: Inflammation in atherosclerosis. Nature 2002; 420: 868–874. [DOI] [PubMed] [Google Scholar]
- 3. Schroeder AP, Falk E: Pathophysiology and inflammatory aspects of plaque rupture. Cardiol Clin 1996; 14: 211–220. [DOI] [PubMed] [Google Scholar]
- 4. Fichtlscherer S, Heeschen C, Zeiher AM: Inflammatory markers and coronary artery disease. Curr Opin Pharmacol 2004; 4: 124–131. [DOI] [PubMed] [Google Scholar]
- 5. Alpert JS, Thygesen K, Antman E, Bassand JP: Myocardial infarction redefined‐ a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36: 959–969. [DOI] [PubMed] [Google Scholar]
- 6. Zairis MN, Adamopoulou EN, Manousakis SJ, Lyras AG, Bibis GP, et al.: The impact of hs C‐reactive protein and other inflammatory biomarkers on long‐term cardiac mortality in patients with acute coronary syndromes. Atherosclerosis 2006; Doi: 10.1016/j.atherosclerosis.2006.08.008. [DOI] [PubMed] [Google Scholar]
- 7. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH: Plasma concentration of interleukin‐6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767–1772. [DOI] [PubMed] [Google Scholar]
- 8. Koukkunen H, Penttila K, Kemppainen A, Halinen M, Penttila I, et al.: C‐reactive protein, fibrinogen, interleukin‐6 and tumor necrosis factor‐alpha in the prognostic classification of unstable angina pectoris. Ann Med 2001; 33: 37–47. [DOI] [PubMed] [Google Scholar]
- 9. Ohtsuka T, Hamada M, Inoue K, Ohshima K, Sujzuki J, et al.: Relation of circulating interleukin‐6 to left ventricular remodeling in patients with reperfused anterior myocardial infarction. Clin Cardiol 2004; 27: 417–420. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Phipps RP: Atherosclerosis: the emerging role of inflammation and the CD40‐CD40 ligand system. Proc Natl Acad Sci U S A 2000; 97: 6930–6932. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Mach F, Schonbeck U, Bonnefoy JY, Pober JS, Libby P: Activation of monocyte/macrophage functions related to acute atheroma complicaion by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation 1997; 96: 396–399. [DOI] [PubMed] [Google Scholar]
- 12. Shah PK, Falk E, Badimon JJ, Fernandez‐Ortiz A, Mailhac A, et al.: Human monocyte‐derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix‐degrading metalloproteinases and implications for plaque rupture. Circulation 1995; 92: 1565–1569. [PubMed] [Google Scholar]
- 13. Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, et al.: Soluble CD40L ligand in acute coronary syndromes. N Engl J Med 2003; 348: 1104–1111. [DOI] [PubMed] [Google Scholar]
- 14. Varo N, de Lemos JA, Libby P, Morrow DA, Murphy SA, et al.: Soluble CD40L: risk prediction after acute coronary syndromes. Circulation 2003; 108: 1049–1052. [DOI] [PubMed] [Google Scholar]
- 15. Inokubo Y, Hanada H, Ishizaka H, Fukushi T, Kamada T, et al.: Plasma levels of matrix metalloproteinase‐9 and tissue inhibitor of metalloproteinase‐1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J 2001; 141: 211–217. [DOI] [PubMed] [Google Scholar]
- 16. Manginas A, Bei E, Chaidaroglou A, Degiannis D, Koniavitou K, et al.: Peripheral levels of matrix metalloproteinase‐9, interleukin‐6, and C‐reactive protein are elevated in patients with acute coronary syndromes: correlations with serum troponin I. Clin Cardiol 2005; 28: 182–186. [DOI] [PMC free article] [PubMed] [Google Scholar]